| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1999;30:1583-1590.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Clinical Radiology (J.O.K., R.L.V., Y.L., P.L.K.P., P.A.V., K.K., H.J.A.), Clinical Physiology and Nuclear Medicine (J.T.K., E.J.V.), and Neurology (J.N., R.R., J.S.), Kuopio University Hospital (Finland); Department of Neuroradiology, Aarhus University Hospital (L.Ø.) (Denmark); and Department of Radiology, Helsinki University Central Hospital (J.P., H.J.A.) (Finland).
| Abstract |
|---|
|
|
|---|
MethodsForty-six patients with acute ischemic stroke underwent DWI and PWI on days 1, 2, and 8. No patient received thrombolysis. Twenty-three patients underwent single-photon emission CT in the acute phase. Lesion volumes were measured from DWI, SPECT, and maps of relative cerebral blood flow calculated from PWI.
ResultsThe mean volume of infarcted tissue detected by DWI increased from 46.1 to 75.6 cm3 between days 1 and 2 (P<0.001; n=46) and to 78.5 cm3 after 1 week (P<0.001; n=42). The perfusion-diffusion mismatch correlated with infarct growth (r=0.699, P<0.001). The volume of hypoperfusion on the initial PWI correlated with final infarct size (r=0.827, P<0.001). The hypoperfusion volumes detected by PWI and SPECT correlated significantly (r=0.824, P<0.001).
ConclusionsCombined DWI and PWI can predict infarct enlargement in acute stroke. PWI can detect hypoperfused brain tissue in good agreement with SPECT in acute stroke.
Key Words: magnetic resonance imaging, diffusion-weighted penumbra perfusion stroke, acute tomography, emission computed
| Introduction |
|---|
|
|
|---|
Diffusion-weighted MRI (DWI) and perfusion-weighted MRI (PWI) are relatively new methods that can be utilized in acute stroke imaging. DWI is based on the measurement of the diffusion of free water,6 which is decreased in ischemic brain tissue.7 8 DWI is very sensitive to infarcted brain tissue, which is seen as an area of high signal intensity compared with the signal from normal brain. This phenomenon can be investigated more quantitatively by studying the reduction in the apparent diffusion coefficient (ADC),9 which has been detected in animals within minutes of the occlusion of the middle cerebral artery (MCA).10 With PWI, hypoperfused tissue can be detected with the use of paramagnetic contrast agents, for example, gadolinium-based chelates.11 12 On the basis of MR perfusion imaging data, maps of relative cerebral blood flow (rCBF) can be calculated.13 14
Single-photon emission CT (SPECT) is a well-characterized method for measuring cerebral blood flow (CBF), and its general availability makes it a potential tool in assessing acute ischemic stroke.15 However, SPECT does not provide morphological information, and it may be logistically difficult to combine it with CT or MRI. Since PWI can be combined with DWI in a single imaging session, it could represent an alternative to SPECT in imaging brain perfusion. Experiences in detecting intraparenchymal hemorrhage with susceptibility-weighted MRI at 1.5 T seem promising,16 17 which may support the potential role of MRI as the primary imaging tool in acute stroke.
The target of novel therapeutic approaches is the ischemic penumbra, where the hypoperfused brain tissue is functionally impaired but salvageable if perfusion is restored.18 If the volume of hypoperfused tissue differs from the volume of tissue with decreased diffusion (perfusion-diffusion mismatch), this volume difference may be used as an estimate of the ischemic penumbra. The ischemic penumbra may also be estimated in terms of the absolute CBF relative to the ischemic limit.19
The purpose of the present study was to evaluate the potential of combined DWI and PWI in acute (<24 hours) ischemic stroke to predict infarct growth and final infarct size. We studied this by comparing initial infarct volume with the volume of hypoperfused tissue and by correlating the size of this perfusion-diffusion mismatch to the subsequent change in infarct volume. In addition, our aim was to compare PWI with SPECT, which is a well-established method used to measure CBF.
| Subjects and Methods |
|---|
|
|
|---|
The first MRI was performed as soon as possible after the patient's admission to the hospital. The time delay from the CT examination to the first MRI was 3.0±2.6 (mean±SD) hours. If the patient could not undergo the first MRI within 24 hours of the onset of symptoms or the time when he or she was last seen healthy, the patient was excluded from the study. The first MRI (n=46) was performed 9.9±5.4 hours, the second MRI (n=46) 30.7±6.7 hours, and the third MRI (n=42) 7.1 days ±16 hours after the onset of symptoms. Patients with general contraindications to MRI (eg, cardiac pacemakers, claustrophobia) were excluded as well as patients who were too unstable for MRI. The second MRI was performed on day 2, and the third MRI was performed 1 week after the onset of symptoms. Twenty-three of 46 patients also underwent SPECT in the acute phase, 14 of them on day 1 and 9 of them on day 2 after the onset of symptoms.
No patient received experimental neuroprotective agents, but 1 patient received placebo as part of the ECASS II trial.20 No patient was treated with thrombolysis. Two patients were treated with intravenous heparinoid as part of the Euro-TOAST (Trial of Org 10172 in Acute Stroke Treatment) study protocol. Five patients were treated with intravenous heparin for stroke progression, and 6 patients with cardioembolic stroke were treated with warfarin. Other patients were treated with aspirin with or without dipyridamole and received standard supportive therapy for acute ischemic stroke.
Informed consent was obtained from the patient or the patient's relative. The study design was approved by the ethics committee of our institution.
Evaluation of CT Findings
Ischemic CT findings were not an exclusion criterion.
They were categorized as follows: (1) no acute ischemic
findings, (2) subtle ischemic findings, and (3) definite
ischemic findings. Detailed comparison of CT and MRI findings
was not performed because of the time delay between CT and MRI.
MRI Protocol
Each MRI examination consisted of DWI, PWI, and conventional
imaging. The total imaging time was approximately 20 minutes. All MRI
examinations were performed with a 1.5-T echo-planar imaging
(EPI)capable whole body scanner (Magnetom Vision, Siemens Medical
Systems) with the use of a head coil and standard restraints.
DWI was performed with an EPI spin-echo sequence (repetition time, 4000 milliseconds; echo time, 103 milliseconds). Nineteen axial slices tilted along the orbitomeatal line covering the whole supratentorial brain were imaged (slice thickness, 5 mm; interslice gap, 1.5 mm; field of view, 260 mm; matrix size, 96x128 interpolated to 256x256; acquisition time, 20 seconds). A T2-weighted reference image (b value, 0 s/mm2) and 3 diffusion-weighted images with orthogonally applied diffusion gradients (b value, 1000 s/mm2) were collected.
Perfusion imaging also used an EPI spin-echo sequence (repetition time, 1500 milliseconds; echo time, 78 milliseconds) and was targeted to the central area of ischemia. Seven axial slices (slice thickness, 5 mm; interslice gap, 1.5 mm; field of view, 260 mm; matrix size, 116x256) were acquired. The positions and tilt of the slices were set to match the 7 slices on DWI that contained the largest diffusion defects. The 7 slices were imaged 40 times every 1.5 seconds, with a total imaging time of 1 minute. Before the injection of contrast medium, 4 sets of baseline images were collected. More baseline images resulted from the time delay between the intravenous injection of the contrast medium and its arrival to the cerebral arterial circulation. Gadopentetate dimeglumine (Magnevist, Schering AG; 0.2 mmol/kg body wt) was injected into the antecubital vein with an 18-gauge cannula. The injection was performed at a speed of 5 mL/s with an MR-compatible power injector (Spectris, Medrad). The bolus of contrast medium was followed by a 15-mL bolus of saline at the same injection rate. Because DWI and conventional imaging were performed before PWI, the intravenous line was kept open by flushing it with 0.25 mL of saline per minute.
SPECT Imaging Protocol
Technetium-99m ethyl cysteinate dimer was used as
the tracer21 and prepared according to the manufacturer's
instructions (DuPont Pharma/Durham APS). A dose of 550 to 720 MBq,
depending on the body weight of the patient, was injected into the
antecubital vein before or after the MRI examination. The time delay
between MRI and injection of the tracer was limited to 1 hour to
achieve temporally comparable findings in PWI and SPECT. Within 60
minutes of the injection, the high-resolution SPECT acquisition was
performed with a gamma camera equipped with fan-beam collimators
(MultiSPECT 3, Siemens Medical Systems, Inc). A full 360° rotation
was acquired (40 views per detector, each for 35 seconds) with 128x128
pixels in resolution. Along the orbitomeatal line tilted contiguous
transaxial and coronal slices (2 pixels in width; 6 mm) were
reconstructed by filtered backprojection and corrected for
attenuation. The imaging resolution was 8 to 9
mm.22
Postprocessing of the Imaging Data
To minimize the effects of diffusion anisotropy, trace images
(trace of the diffusion tensor) were generated by calculating the
average of the 3 diffusion-weighted images.23 24 ADC maps
were calculated on a pixel-by-pixel basis. The calculation of ADC was
based on the negative slope of the line fitting the 2 points for b
versus ln(SI), where SI is signal intensity. Volumes of decreased
diffusion were measured by drawing regions of interest (ROIs) around
the lesions on the trace images and by multiplying the lesion area by
the slice thickness. The tracings were shared between 2 interpreters
(J.O.K. and Y.L.) blinded to the clinical data. ADC maps were reviewed
to rule out the effects of T2 shine-through, which would have in some
cases caused overestimation of infarcted tissue. The interslice gap was
estimated to contain a lesion of the same size as the slice above it,
and the lesion inside the gap was included in the volume
calculation.
Perfusion raw images were transferred to a UNIX workstation (Sun SPARC
Ultra) for calculation of rCBF maps. Tissue and arterial
contrast agent levels were determined with the assumption of a linear
relationship between transverse relaxivity (
R2) and intravascular
concentration of Gd-DTPA.11 25 26 The shape of the
arterial input function was determined from a few pixels
located at 1 branch of the MCA, showing large signal losses during the
bolus passage. In each imaging pixel, the tissue concentration-time
curve was deconvolved with the arterial input function to
determine the tissue impulse response. CBF was subsequently determined
as the height of the deconvolved tissue impulse
response.13 14
The volume of decreased perfusion was determined visually by 1 interpreter (J.O.K.) by drawing a ROI around the pathological area slice by slice. A commercially available image analysis software package was used (Cheshire, Perceptive Systems, Inc). After the ROIs were multiplied by the slice thickness of 5 mm and the interslice gaps, they were summed to give the total volume of hypoperfused tissue in the 7 imaged slices. However, the lesion area in the lowermost lesion-containing slice was multiplied only by the slice thickness but not by the gap thickness. Because an acute hypoperfusion could not be distinguished from probable old perfusion defects, the interpreter was not blinded to the diffusion imaging findings but was blinded to the clinical data of the patients.
To test the interobserver variability in the measurements, 2 observers (J.O.K. and Y.L.) independently drew ROIs in 80 trace images and 70 rCBF maps of 10 randomly selected patients. To test intraobserver reproducibility, 1 of the observers performed the measurements twice in 5 randomly selected patients, with an interval of at least 6 months between measurements.
A semiautomatic brain quantification program (Siemens Medical Systems, Inc) was used to analyze the size of the perfusion defect on SPECT. The perfusion defect was defined as cortical regions with count rates <60% of the maximal cortical rate. The ROIs were manually drawn onto the consecutive slices by an experienced rater who was not aware of the PWI findings or the clinical status of the patient. However, the rater was aware of the DWI findings to be able to differentiate between acute and chronic perfusion defects on SPECT.
Volumetrics
The total infarct volume was measured from all DWI slices
containing the lesion. Because of the limited number of slices in
perfusion imaging, the true volume of hypoperfusion could not be
entirely measured in 23 cases of larger infarctions. In those cases,
the volumes of decreased diffusion were also calculated from the 7
slices corresponding to the slices in perfusion imaging.
The following volumes were measured: (1) total volume of tissue with decreased diffusion; (2) volume of hypoperfused tissue in rCBF maps in the 7 slices included in PWI; (3) volume of tissue with decreased diffusion limited to the 7 slices comparable to PWI of the same day; (4) volumes of decreased diffusion on day 2 and at 1 week from the same slice positions where PWI was performed on day 1 to compare the same tissue volume when infarct growth and final infarct size were considered; and (5) volumes of hypoperfused tissue on SPECT calculated from the same 7 slices corresponding to the area of PWI on the same day. The contiguous slices on SPECT were 6 mm thick, causing a slight inconsistency compared with seven 5-mm-thick PWI slices with 1.5-mm gaps.
The perfusion-diffusion mismatch was calculated by subtracting the DWI lesion volume from the hypoperfusion volume in rCBF maps. Infarct growth was defined as the increase in infarcted tissue volumes measured from the DWI slices matching the positions of the 7 slices on the initial PWI.
Assessment of the Neurological Status of the Patient
The mean National Institutes of Health Stroke Scale
(NIHSS)27 was measured by a neurologist (J.N., R.R., or
J.S.) on day 1 and at 1 week. The initial mean NIHSS score was
12.4±8.1 (mean±SD), ranging from 0 (no symptoms measured by the
NIHSS) to 38.
Statistical Analysis
Since there was a significant deviation from normal
distribution, nonparametric tests were used to test the
significance of volume differences. The significance of changes in mean
infarct volumes and the differences between infarct volumes and
hypoperfusion volumes were tested with the Wilcoxon
matched-pairs signed rank test. The Spearman correlation coefficient
was used to calculate (1) correlation between hypoperfusion volumes in
PWI maps and SPECT, (2) correlation between perfusion-diffusion
mismatch and infarct growth, (3) correlation between initial
hypoperfusion volume in PWI maps and infarct size at 1 week, and (4)
interobserver variability and intraobserver reproducibility by 2
measurers for measured DWI and PWI for both lesion area (slice by
slice) and lesion volume (patient by patient).
Furthermore, the patient population was divided into 2 groups according
to the perfusion-diffusion mismatch: group 1, ratio of PWI lesion
volume to DWI lesion volume <1.10; and group 2, ratio of PWI lesion
volume to DWI lesion volume
1.10. After this dichotomization, the
Mann-Whitney U test was used to test whether the change in
the NIHSS score during the week differed significantly between groups 1
and 2. The Mann-Whitney U test was also used to test whether
the anticoagulant treatment with warfarin or intravenous
heparin was associated with infarct growth during the week. A
P-value <0.05 was considered statistically significant.
Statistical analysis was performed with a statistical software
package (SPSS Win 7.5, SPSS Inc).
| Results |
|---|
|
|
|---|
Four of 46 patients did not undergo the third MRI (3 died, 1 refused). DWI was successfully completed in every MRI. The hypoperfusion volume in PWI was not available in 8 cases on the first day (because of patient motion [n=5], malfunction of the scanner [n=1], or operator-dependent error [n=2]). Hypoperfusion volume in PWI was not available in 13 cases on day 2 (patient motion [n=6], serious imaging artifact [n=4], or operator-dependent error [n=3]) and in 3 cases at 1 week (malfunction of the scanner [n=2], operator-dependent error [n=1]). PWI was thus successfully performed on 38 patients on day 1, on 33 patients on day 2, and on 39 patients at 1 week.
The mean volume of infarcted tissue measured from the diffusion trace
images increased from 46.1 cm3 (n=46) on day 1 to
75.6 cm3 on day 2 (n=46; P<0.001).
When measured at 1 week, the mean infarct volume had still slightly
increased to 78.5 cm3 (n=42; P<0.001)
(Table 1
). A
representative case showing the infarct growth is
presented in Figure 1
.
|
|
The volumes of hypoperfused tissue on PWI compared with the volume of
infarcted tissue measured from the corresponding DWI slices are
presented in Table 2
. On day 1,
the infarcted tissue was not totally covered by 7 slices in 23
patients. The mean volume of infarcted tissue outside the 7 slices was
15.8 cm3. On day 1, the hypoperfusion volume on
rCBF maps was significantly greater than the infarct volume on DWI
(P<0.001). On day 2, the hypoperfusion volume was still
greater than the infarct volume (P=0.014). At 1 week, the
hypoperfusion volume had decreased and was actually smaller than the
infarct volume on DWI. This is probably due to reperfusion in the
infarcted tissue, and in a few cases findings suggesting hyperperfusion
were detected.
|
The perfusion-diffusion mismatch correlated statistically significantly
with infarct growth between days 1 and 2 (r=0.586,
P<0.001; n=38) and between day 1 and 1 week
(r=0.699, P<0.001; n=34). A typical case in
which the perfusion-diffusion mismatch detects tissue at risk, part of
which eventually proceeds to infarction, is shown in Figure 1
. A
case with absence of perfusion-diffusion mismatch on day 1 and no
significant infarct growth is shown in Figure 2
. The hypoperfusion volume measured from
rCBF maps on day 1 correlated statistically significantly with the
final infarct size measured from DWI at 1 week after the onset of
symptoms (r=0.827, P<0.001; n=34).
|
The hypoperfusion volume on SPECT in the acute phase (mean, 82.5±124.8
cm3) correlated strongly with the hypoperfusion
volume measured from rCBF maps (mean, 79.2±78.3
cm3) on the same day (r=0.824,
P<0.001; n=23). Note that these mean volumes result from
the PWI of day 1 or 2, depending on the day when SPECT was performed.
Figure 3
shows a comparison of PWI with
SPECT.
|
Infarct growth during the week in patients receiving anticoagulant treatment did not differ significantly (P=0.81) from infarct growth in patients not receiving anticoagulant treatment.
In interobserver variability analysis, the DWI lesion areas
measured slice by slice correlated well between the 2 measurers
(r=0.964, P<0.01; n=80 slices). The hypoperfusion areas
measured from rCBF maps slice by slice also correlated well between 2
measurers (r=0.907, P<0.01; n=70 slices) (Figure 4
). When lesion volumes were calculated
patient by patient, the correlations between volumes measured by 2
measurers were also significant for DWI (r=0.976,
P<0.01; n=10) and PWI (r=0.976,
P<0.01; n=10).
|
In intraobserver reproducibility analysis, the correlation of 2 measurements slice by slice was significant for DWI (r=0.950, P<0.01; n=40 slices) and PWI (r=0.802, P<0.01; n=35 slices).
During the week, the mean NIHSS score changed from 12.4±8.1 to
9.3±9.6, when 3 patients had died. The NIHSS score change did not
differ significantly (P=0.52) between groups 1 (ratio of PWI
to DWI <1.10; n=7) and 2 (ratio of PWI to DWI
1.10; n=28). Three
patients who died were excluded from the analysis because death
is not coded in the NIHSS. However, they all had perfusion-diffusion
mismatch ratio >1.10. In group 2, the perfusion-diffusion mismatch was
59.2±49.1 cm3. In group 1, the
perfusion-diffusion mismatch was 0.4±2.5
cm3.
| Discussion |
|---|
|
|
|---|
Because DWI at present cannot totally characterize the hemodynamics of the ischemic process, other groups have also used combined DWI and PWI to distinguish the ischemic penumbra from permanently damaged tissue. In this approach, perfusion-diffusion mismatch is used to estimate the presence and size of the ischemic penumbra. Warach et al35 first demonstrated the ability of combined DWI and single-slice PWI to predict clinical outcome. In the series of Sorensen et al,34 the lesion on DWI was generally smaller than the hypoperfusion volume in maps of relative cerebral blood volume. Baird et al36 detected, in a subgroup of 13 patients, that perfusion-diffusion mismatch (mean transit time as the perfusion parameter) in the acute phase may be predictive of infarct growth. Rordorf et al37 observed that the infarct more often showed progression into the surrounding hypoperfused tissue (detected by maps of relative cerebral blood volume) if there was a MCA stem occlusion on MR angiography. Tong et al38 demonstrated a correlation of lesion volumes on DWI and PWI (maps of time to peak) with clinical status after 24 hours and infarct size at 1 week. Barber et al39 detected that perfusion-diffusion mismatch (relative mean transit time as the perfusion parameter) predicted DWI lesion growth.
We were able to perform DWI in all 46 patients and PWI in 38 of 46 patients (83%) in the acute phase of ischemic stroke. Patient movement or lack of cooperation was responsible for 5 of 8 failures of PWI. We conclude that DWI and PWI can be performed in the routine diagnosis of acute stroke.
There was good agreement between volumes of decreased rCBF measured by
SPECT and PWI. Lesions that were apparently small on SPECT were
somewhat larger on PWI, probably because of the difference in
resolution of these techniques (Figure 5
).
|
We performed the third MRI after 1 week from the onset of stroke to
establish the final size of the infarct. The initial hypoperfusion
volumes in rCBF maps showed good correlation with the infarct size at 1
week (Figure 6
). CBF begins to change
only when cerebral perfusion pressure falls below the range of normal
autoregulation, ie, when hypoperfusion is severe. One would therefore
expect decreased CBF to be clearly associated with a high risk of
subsequent infarction. Figure 7
shows
perfusion-diffusion mismatch versus lesion growth on DWI during the
week. Note that hypoperfusion volume on the rCBF map is usually larger
than the tissue that eventually proceeds to infarction (Figure 6
). Even though there is a decrease in CBF, neuronal function is
maintained until CBF falls below a relatively fixed threshold (
20
mL/100 g per minute). Below this threshold, survival time is limited.
We therefore speculate that future risk assessments based on the degree
of rCBF deficit (relative to white matter flow rates, for example) and
the duration of ischemia might possibly improve the predictive
value of rCBF maps.
|
|
rCBF maps seem to be accurate prognostic markers in demonstrating tissue at risk. However, one should take into account the time from the onset of symptoms, since the brain tissue is able to survive decreased blood flow only for a relatively short time. In this study we used perfusion-diffusion mismatch as a tool to estimate the ischemic penumbra. Other hypotheses regarding how the ischemic penumbra could be estimated in a patient also exist, for example, by measuring absolute CBF.
There are certain limitations in our study. The patients did not receive thrombolytic treatment, but we think that this makes our material fairly representative of the natural course of ischemic stroke during the first week after stroke onset. Anticoagulant treatment did not affect infarct growth. The data presented here are not confounded by reperfusion other than what may have occurred spontaneously.
Spin-echo PWI, which is sensitive to microvascular perfusion, could be performed in only 7 slices to maintain the temporal resolution of 1.5 seconds between the measurements. We imaged a representative sample of the infarct to be covered with PWI by matching the middle PWI slice with the DWI slice containing the largest diffusion defect. This slice was in most cases located in the center of the infarct but, because the infarct can expand in any direction, the imaged areas in PWI are not strictly comparable.
There was a large variation in infarct size in this population, and patients were selected from a patient population with different neurological symptoms. Patient recruitment was partly simultaneous with the ECASS II trial,20 and 1 patient received placebo before the first MRI. Otherwise, patients were not considered for thrombolysis because it is not an approved treatment for acute ischemic stroke at our hospital, and the majority of patients were admitted to the hospital >3 hours from the onset of symptoms. We believe that our patient population is representative and reflects the reality in most clinical institutions at present.
Our results show that the infarct enlarges between days 1 and 2, which is in agreement with the study of Baird et al.36 This supports the view that there could be a place for the use of neuroprotective agents later than only a few hours from the onset of symptoms. Although neuroprotection has been beneficial in experimental stroke in animals, no neuroprotective agent has yet proved effective in humans.40 The dynamic nature of the ischemic penumbra and different mechanisms of potential treatments have questioned the concept of a universal narrow time window.41
Hypoperfusion on rCBF maps correlated well with hypoperfusion on SPECT
images (Figure 5
). Unlike SPECT, our MR method allows direct
visualization of irreversibly damaged tissue by DWI. In clinical
management, thrombolytic treatment is potentially
hazardous in patients with large infarcts,1 giving the
integrated MR examination a potential advantage in clinical decision
making.
The present study is based on a prospective series of acute stroke patients imaged repeatedly with a uniform MRI protocol. The patients did not receive thrombolytic treatment, and therefore the results reflect the natural history of acute ischemic stroke. CT was performed initially as part of the clinical routine, and SPECT was used as a reference method for MR perfusion imaging. We conclude that combined DWI and PWI can be used in estimating the presence and the size of the penumbra in acute nonhemorrhagic ischemic stroke. The penumbra on day 1, estimated as perfusion-diffusion mismatch, correlates statistically significantly with the growth of infarct detected as an increase in the volume of decreased diffusion. Finally, hypoperfusion volume on rCBF maps correlated significantly with final infarct size at 1 week. The combination of DWI and PWI is a powerful tool to predict and follow the course of acute ischemic stroke.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received March 12, 1999; revision received May 11, 1999; accepted May 18, 1999.
| References |
|---|
|
|
|---|
2.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von
Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M.
Intravenous thrombolysis with recombinant
tissue plasminogen activator for acute
hemispheric stroke: the European Cooperative Acute Stroke Study
(ECASS). JAMA. 1995;274:10171025.
3.
von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello
S, Manelfe C, Bluhmki E, Ringleb P, Meier DH, Hacke W. Acute stroke:
usefulness of early CT findings before thrombolytic
therapy. Radiology. 1997;205:327333.
4. Bryan RN, Levy LM, Whitlow WD, Killian JM, Preziosi TJ, Rosario JA. Diagnosis of acute cerebral infarction: comparison of CT and MR imaging. AJNR Am J Neuroradiol. 1991;12:611620.[Abstract]
5. Yuh WT, Crain MR, Loes DJ, Greene GM, Ryals TJ, Sato Y. MR imaging of cerebral ischemia: findings in the first 24 hours. AJNR Am J Neuroradiol. 1991;12:621629.[Abstract]
6. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys. 1965;42:288292.
7.
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis
E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions:
application to diffusion and perfusion in neurologic disorders.
Radiology. 1986;161:401407.
8. Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, Asgari H, Norman D. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol. 1990;11:423429.[Abstract]
9.
Schlaug G, Siewert B, Benfield A, Edelman RR, Warach
S. Time course of the apparent diffusion coefficient (ADC) abnormality
in human stroke. Neurology. 1997;49:113119.
10.
Reith W, Hasegawa Y, Latour LL, Dardzinski BJ, Sotak
CH, Fisher M. Multislice diffusion mapping for 3-D evolution of
cerebral ischemia in a rat stroke model. Neurology. 1995;45:172177.
11. Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, Brady TJ. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med. 1988;6:164174.[Medline] [Order article via Infotrieve]
12. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, Vevea JM, Cohen MS, Pykett IL, Brady TJ. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990;14:538546.[Medline] [Order article via Infotrieve]
13. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, part I: mathematical approach and statistical analysis. Magn Reson Med. 1996;36:715725.[Medline] [Order article via Infotrieve]
14. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, part II: experimental comparison and preliminary results. Magn Reson Med. 1996;36:726736.[Medline] [Order article via Infotrieve]
15.
Holman BL, Devous MD Sr. Functional brain SPECT: the
emergence of a powerful clinical method. J Nucl Med. 1992;33:18881904.
16.
Patel MR, Edelman RR, Warach S. Detection of hyperacute
primary intraparenchymal hemorrhage by magnetic resonance
imaging. Stroke. 1996;27:23212324.
17.
Schellinger PD, Jansen O, Fiebach JB, Hacke W, Sartor
K. A standardized MRI stroke protocol: comparison with CT in hyperacute
intracerebral hemorrhage. Stroke. 1999;30:765768.
18.
Astrup J, Siesjo BK, Symon L. Thresholds in cerebral
ischemia: the ischemic penumbra. Stroke. 1981;12:723725.
19.
Scharbrough F, Messick J Jr, Sundt T Jr. Correlation of
continuous electroencephalograms with cerebral blood flow measurements
during carotid endarterectomy. Stroke. 1973;4:674683.
20. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:12451251.[Medline] [Order article via Infotrieve]
21.
Holman BL, Hellman RS, Goldsmith SJ, Mena IG, Leveille
J, Gherardi PG, Moretti JL, Bischof-Delaloye A, Hill TC, Rigo PM, van
Heertum RL, Ell PJ, Buell U, de Roo MC, Morgan RA. Biodistribution,
dosimetry, and clinical evaluation of technetium-99 m ethyl
cysteinate dimer in normal subjects and in patients with chronic
cerebral infarction. J Nucl Med. 1989;30:10181024.
22. Kuikka JT, Tenhunen-Eskelinen M, Jurvelin J, Kiiliäinen H. Physical performance of the Siemens MultiSPECT 3 gamma camera. Nucl Med Commun. 1993;14:490497.[Medline] [Order article via Infotrieve]
23. van Gelderen P, de Vleeschouwer MH, DesPres D, Pekar J, van Zijl PC, Moonen CT. Water diffusion and acute stroke. Magn Reson Med. 1994;31:154163.[Medline] [Order article via Infotrieve]
24.
Ulug AM, Beauchamp N Jr, Bryan RN, van Zijl PC.
Absolute quantitation of diffusion constants in human stroke.
Stroke. 1997;28:483490.
25. Fisel CR, Ackerman JL, Buxton RB, Garrido L, Belliveau JW, Rosen BR, Brady TJ. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med. 1991;17:336347.[Medline] [Order article via Infotrieve]
26. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med. 1994;31:601610.[Medline] [Order article via Infotrieve]
27.
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG,
Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of
acute cerebral infarction: a clinical examination scale.
Stroke. 1989;20:864870.
28. Lutsep HL, Albers GW, DeCrespigny A, Kamat GN, Marks MP, Moseley ME. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol. 1997;41:574580.[Medline] [Order article via Infotrieve]
29. Lovblad KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR, Warach S. Clinical experience with diffusion-weighted MR in patients with acute stroke. AJNR Am J Neuroradiol. 1998;19:10611066.[Abstract]
30.
Minematsu K, Li L, Sotak CH, Davis MA, Fisher M.
Reversible focal ischemic injury demonstrated by
diffusion-weighted magnetic resonance imaging in rats.
Stroke. 1992;23:13041310.
31. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. J Cereb Blood Flow Metab. 1998;18:583609.[Medline] [Order article via Infotrieve]
32. Warach S, Wielopolski P, Edelman RR. Identification and characterization of the ischemic penumbra of acute human stroke using echo planar diffusion and perfusion imaging. Proc Soc Magn Reson Med. 1993;1:249. Abstract.
33.
Marks MP, de Crespigny A, Lentz D, Enzmann DR, Albers
GW, Moseley ME. Acute and chronic stroke: navigated spin-echo
diffusion-weighted MR imaging. Radiology. 1996;199:403408.
34.
Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev
MH, Huang-Hellinger FR, Reese TG, Weisskoff RM, Davis TL, Suwanwela N,
Can U, Moreira JA, Copen WA, Look RB, Finklestein SP, Rosen BR,
Koroshetz WJ. Hyperacute stroke: evaluation with combined
multisection diffusion-weighted and hemodynamically
weighted echo-planar MR imaging. Radiology. 1996;199:391401.
35. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab. 1996;16:5359.[Medline] [Order article via Infotrieve]
36. Baird AE, Benfield A, Schlaug G, Siewert B, Lovblad KO, Edelman RR, Warach S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997;41:581589.[Medline] [Order article via Infotrieve]
37.
Rordorf G, Koroshetz WJ, Copen WA, Cramer SC, Schaefer
PW, Budzik RF Jr, Schwamm LH, Buonanno F, Sorensen AG, Gonzalez G.
Regional ischemia and ischemic injury in patients with
acute middle cerebral artery stroke as defined by early
diffusion-weighted and perfusion-weighted MRI. Stroke. 1998;29:939943.
38.
Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP,
Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with
NIHSS score in acute (<6.5 hour) ischemic stroke.
Neurology. 1998;50:864870.
39.
Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP,
Jolley D, Donnan GA, Tress BM, Davis SM. Prediction of stroke outcome
with echoplanar perfusion- and diffusion-weighted MRI.
Neurology. 1998;51:418426.
40.
Beauchamp NJ Jr, Bryan RN. Acute cerebral
ischemic infarction: a pathophysiologic review and radiologic
perspective. AJR Am J Roentgenol. 1998;171:7384.
41.
Baron JC, von Kummer R, del Zoppo GJ. Treatment of
acute ischemic stroke: challenging the concept of a rigid and
universal time window. Stroke. 1995;26:22192221.
This article has been cited by other articles:
![]() |
P.G. Kranz and J.D. Eastwood Does Diffusion-Weighted Imaging Represent the Ischemic Core? An Evidence-Based Systematic Review AJNR Am. J. Neuroradiol., June 1, 2009; 30(6): 1206 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.M. Provenzale, K. Shah, U. Patel, and D.C. McCrory Systematic Review of CT and MR Perfusion Imaging for Assessment of Acute Cerebrovascular Disease AJNR Am. J. Neuroradiol., September 1, 2008; 29(8): 1476 - 1482. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kimura, Y. Iguchi, K. Shibazaki, Y. Terasawa, T. Inoue, J. Uemura, and J. Aoki Large Ischemic Lesions on Diffusion-Weighted Imaging Done Before Intravenous Tissue Plasminogen Activator Thrombolysis Predicts a Poor Outcome in Patients With Acute Stroke Stroke, August 1, 2008; 39(8): 2388 - 2391. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Furlan, D. Eyding, G. W. Albers, Y. Al-Rawi, K. R. Lees, H. A. Rowley, C. Sachara, M. Soehngen, S. Warach, W. Hacke, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset Stroke, May 1, 2006; 37(5): 1227 - 1231. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.S. Butcher, M. Parsons, L. MacGregor, P.A. Barber, J. Chalk, C. Bladin, C. Levi, T. Kimber, D. Schultz, J. Fink, et al. Refining the Perfusion-Diffusion Mismatch Hypothesis Stroke, June 1, 2005; 36(6): 1153 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hacke, G. Albers, Y. Al-Rawi, J. Bogousslavsky, A. Davalos, M. Eliasziw, M. Fischer, A. Furlan, M. Kaste, K. R. Lees, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase Stroke, January 1, 2005; 36(1): 66 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Perkio, L. Soinne, L. Ostergaard, J. Helenius, A. Kangasmaki, S. Martinkauppi, O. Salonen, S. Savolainen, M. Kaste, T. Tatlisumak, et al. Abnormal Intravoxel Cerebral Blood Flow Heterogeneity in Human Ischemic Stroke Determined by Dynamic Susceptibility Contrast Magnetic Resonance Imaging Stroke, January 1, 2005; 36(1): 44 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sobesky, O. Z. Weber, F.-G. Lehnhardt, V. Hesselmann, A. Thiel, C. Dohmen, A. Jacobs, M. Neveling, and W.-D. Heiss Which Time-to-Peak Threshold Best Identifies Penumbral Flow?: A Comparison of Perfusion-Weighted Magnetic Resonance Imaging and Positron Emission Tomography in Acute Ischemic Stroke Stroke, December 1, 2004; 35(12): 2843 - 2847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Law, A. M. Saindane, Y. Ge, J. S. Babb, G. Johnson, L. J. Mannon, J. Herbert, and R. I. Grossman Microvascular Abnormality in Relapsing-Remitting Multiple Sclerosis: Perfusion MR Imaging Findings in Normal-appearing White Matter Radiology, June 1, 2004; 231(3): 645 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, J. O. Karonen, R. L. Vanninen, J. Nuutinen, A. Koskela, S. Soimakallio, and H. J. Aronen Acute Ischemic Stroke: Predictive Value of 2D Phase-Contrast MR Angiography--Serial Study with Combined Diffusion and Perfusion MR Imaging Radiology, May 1, 2004; 231(2): 517 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-C. Koennecke Editorial Comment--Challenging the Concept of a Dynamic Penumbra in Acute Ischemic Stroke Stroke, October 1, 2003; 34(10): 2434 - 2435. [Full Text] [PDF] |
||||
![]() |
K. Butcher, M. Parsons, T. Baird, A. Barber, G. Donnan, P. Desmond, B. Tress, and S. Davis Perfusion Thresholds in Acute Stroke Thrombolysis Stroke, September 1, 2003; 34(9): 2159 - 2164. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Higashida and A. J. Furlan Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke Stroke, August 1, 2003; 34 (8): e109 - e137. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. de Crespigny Editorial Comment--Mismatch or Misconception? Stroke, July 1, 2003; 34(7): 1683 - 1685. [Full Text] [PDF] |
||||
![]() |
R. E. Latchaw, H. Yonas, G. J. Hunter, W. T.C. Yuh, T. Ueda, A. G. Sorensen, J. L. Sunshine, J. Biller, L. Wechsler, R. Higashida, et al. Guidelines and Recommendations for Perfusion Imaging in Cerebral Ischemia: A Scientific Statement for Healthcare Professionals by the Writing Group on Perfusion Imaging, From the Council on Cardiovascular Radiology of the American Heart Association Stroke, April 1, 2003; 34(4): 1084 - 1104. [Full Text] [PDF] |
||||
![]() |
P. W. Schaefer, G. J. Hunter, J. He, L. M. Hamberg, A. G. Sorensen, L. H. Schwamm, W. J. Koroshetz, and R. G. Gonzalez Predicting Cerebral Ischemic Infarct Volume with Diffusion and Perfusion MR Imaging AJNR Am. J. Neuroradiol., November 1, 2002; 23(10): 1785 - 1794. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kikuchi, K. Murase, H. Miki, Y. Yasuhara, Y. Sugawara, T. Mochizuki, J. Ikezoe, and S. Ohue Quantitative Evaluation of Mean Transit Times Obtained with Dynamic Susceptibility Contrast-Enhanced MR Imaging and with 133Xe SPECT in Occlusive Cerebrovascular Disease Am. J. Roentgenol., July 1, 2002; 179(1): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ezzeddine, M. H. Lev, C. T. McDonald, G. Rordorf, J. Oliveira-Filho, F. G. Aksoy, J. Farkas, A. Z. Segal, L. H. Schwamm, R. G. Gonzalez, et al. CT Angiography With Whole Brain Perfused Blood Volume Imaging: Added Clinical Value in the Assessment of Acute Stroke Stroke, April 1, 2002; 33(4): 959 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. N. Thijs, A. Adami, T. Neumann-Haefelin, M. E. Moseley, and G. W. Albers Clinical and Radiological Correlates of Reduced Cerebral Blood Flow Measured Using Magnetic Resonance Imaging Arch Neurol, February 1, 2002; 59(2): 233 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamada, O. Wu, R. G. Gonzalez, D. Bakker, L. Ostergaard, W. A. Copen, R. M. Weisskoff, B. R. Rosen, K. Yagi, T. Nishimura, et al. Magnetic Resonance Perfusion-Weighted Imaging of Acute Cerebral Infarction: Effect of the Calculation Methods and Underlying Vasculopathy Stroke, January 1, 2002; 33(1): 87 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Lev, A. Z. Segal, J. Farkas, S. T. Hossain, C. Putman, G. J. Hunter, R. Budzik, G. J. Harris, F. S. Buonanno, M. A. Ezzeddine, et al. Utility of Perfusion-Weighted CT Imaging in Acute Middle Cerebral Artery Stroke Treated With Intra-Arterial Thrombolysis:: Prediction of Final Infarct Volume and Clinical Outcome Editorial Comment: Prediction of Final Infarct Volume and Clinical Outcome Stroke, September 1, 2001; 32(9): 2021 - 2028. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bruening, M. Dichgans, C. Berchtenbreiter, T. Yousry, K. C. Seelos, R. H. Wu, M. Mayer, G. Brix, and M. Reiser Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: Decrease in Regional Cerebral Blood Volume in Hyperintense Subcortical Lesions Inversely Correlates with Disability and Cognitive Performance AJNR Am. J. Neuroradiol., August 1, 2001; 22(7): 1268 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Parsons, Q. Yang, P. A. Barber, D. G. Darby, P. M. Desmond, R. P. Gerraty, B. M. Tress, and S. M. Davis Perfusion Magnetic Resonance Imaging Maps in Hyperacute Stroke : Relative Cerebral Blood Flow Most Accurately Identifies Tissue Destined to Infarct Stroke, July 1, 2001; 32(7): 1581 - 1587. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Wu, W. J. Koroshetz, L. Ostergaard, F. S. Buonanno, W. A. Copen, R. G. Gonzalez, G. Rordorf, B. R. Rosen, L. H. Schwamm, R. M. Weisskoff, et al. Predicting Tissue Outcome in Acute Human Cerebral Ischemia Using Combined Diffusion- and Perfusion-Weighted MR Imaging Stroke, April 1, 2001; 32(4): 933 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kikuchi, K. Murase, H. Miki, T. Kikuchi, Y. Sugawara, T. Mochizuki, J. Ikezoe, and S. Ohue Measurement of Cerebral Hemodynamics with Perfusion-weighted MR Imaging: Comparison with Pre- and Post-acetazolamide 133Xe-SPECT in Occlusive Carotid Disease AJNR Am. J. Neuroradiol., February 1, 2001; 22(2): 248 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pantano, D. Toni, F. Caramia, A. Falcou, M. Fiorelli, C. Argentino, L. M. Fantozzi, and L. Bozzao Relationship between Vascular Enhancement, Cerebral Hemodynamics, and MR Angiography in Cases of Acute Stroke AJNR Am. J. Neuroradiol., February 1, 2001; 22(2): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. COMMITTEE OF THE ASITN Intraarterial Thrombolysis: Ready for Prime Time? AJNR Am. J. Neuroradiol., January 1, 2001; 22(1): 55 - 58. [Full Text] [PDF] |
||||
![]() |
J. O. Karonen, P. L. Kaarina Partanen, R. L. Vanninen, P. A. Vainio, and H. J. Aronen Evolution of MR Contrast Enhancement Patterns during the First Week after Acute Ischemic Stroke AJNR Am. J. Neuroradiol., January 1, 2001; 22(1): 103 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O. Karonen, Y. Liu, R. L. Vanninen, L. Østergaard, P. L. Kaarina Partanen, P. A. Vainio, E. J. Vanninen, J. Nuutinen, R. Roivainen, S. Soimakallio, et al. Combined Perfusion- and Diffusion-weighted MR Imaging in Acute Ischemic Stroke during the 1st Week: A Longitudinal Study Radiology, December 1, 2000; 217(3): 886 - 894. [Abstract] [Full Text] |
||||
![]() |
T. Back, J. G. Hirsch, K. Szabo, and A. Gass Failure to Demonstrate Peri-Infarct Depolarizations by Repetitive MR Diffusion Imaging in Acute Human Stroke Stroke, December 1, 2000; 31(12): 2901 - 2906. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krueger, H. Kugel, M. Grond, A. Thiel, D. Maintz, and K. Lackner Late Resolution of Diffusion-Weighted MRI Changes in a Patient With Prolonged Reversible Ischemic Neurological Deficit After Thrombolytic Therapy Stroke, November 1, 2000; 31(11): 2715 - 2718. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Keir and J. M. Wardlaw Systematic Review of Diffusion and Perfusion Imaging in Acute Ischemic Stroke Stroke, November 1, 2000; 31(11): 2723 - 2731. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Neumann-Haefelin, H.-J. Wittsack, G. R. Fink, F. Wenserski, T.-Q. Li, R. J. Seitz, M. Siebler, U. Modder, and H.-J. Freund Diffusion- and Perfusion-Weighted MRI : Influence of Severe Carotid Artery Stenosis on the DWI/PWI Mismatch in Acute Stroke Stroke, June 1, 2000; 31(6): 1311 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B. Grandin, T. P. Duprez, A. M. Smith, C. Oppenheim, A. Peeters, A. R. Robert, and G. Cosnard Which MR-derived Perfusion Parameters are the Best Predictors of Infarct Growth in Hyperacute Stroke? Comparative Study between Relative and Quantitative Measurements Radiology, May 1, 2002; 223(2): 361 - 370. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |